The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
Open accessAbstract
T cell malignancies represent a group of hematologic cancers with high rates of relapse and mortality in patients for whom no effective targeted therapies exist. The shared expression of target antigens between chimeric antigen receptor (CAR) T cells and malignant T cells has limited the development of CAR-T because of unintended CAR-T fratricide and an inability to harvest sufficient autologous T cells. Here, we describe a fratricide-resistant “off-the-shelf” CAR-T (or UCART7) that targets CD7+ T cell malignancies and, through CRISPR/Cas9 gene editing, lacks both CD7 and T cell receptor alpha chain (TRAC) expression. UCART7 demonstrates efficacy against human T cell acute lymphoblastic leukemia (T-ALL) cell lines and primary T-ALL in vitro and in vivo without the induction of xenogeneic GvHD. Fratricide-resistant, allo-tolerant “off-the-shelf” CAR-T represents a strategy for treatment of relapsed and refractory T-ALL and non-Hodgkin’s T cell lymphoma without a requirement for autologous T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 1×
“Rev [16, 17] using the CalPhosTM Mammalian Transfection Kit (Takara) per the manufacture's instructions.”
MethodHigh-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268 · cited 11×
“GUIDE-seq: The 16 existing dual indexed KAPA libraries constructed for the targeted capture experiment (Supplemental table 3) were utilized for the Guide-Seq amplifications.”
MethodInfluentialTargeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 1×
“Furthermore, insertion of the CAR directly into the TRAC locus, as recently reported [40, 41], or, potentially, the CD7 locus, would further mitigate the risk”
BackgroundSelf-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Guidelines for the Design and Statistical Analysis of Experiments Using Laboratory Animals
Festing, M. F. W., & Altman, D. G. (2002) · ILAR Journal · doi:10.1093/ilar.43.4.244 · Cited by 1,110 · cited 1×
“The determination of sample size and data analysis for this study followed the general guideline for animal studies [24].”
MethodChemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090 · cited 2×
“RNA guides were commercially synthesized (Trilink Biotechnologies San Diego, CA), incorporating 2′-Omethyl and 3′ phosphorothioate bases at the three terminal bases of the 5′ and 3′ ends of the gRNA to protect from nuclease activity [18].”
MethodCooke, K., Kobzik, L., Martin, T., Brewer, J., Delmonte, J. J., Crawford, J., & Ferrara, J. (1996) · Blood · doi:10.1182/blood.v88.8.3230.bloodjournal8883230 · Cited by 963
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
Gomes-Silva, D., Srinivasan, M., Sharma, S., Lee, C. M., Wagner, D. L., Davis, T. H., Rouce, R. H., Bao, G., Brenner, M. K., & Mamonkin, M. (2017) · Blood · doi:10.1182/blood-2017-01-761320 · Cited by 462
Marks, D. I., Paietta, E. M., Moorman, A. V., Richards, S. M., Buck, G., DeWald, G., Ferrando, A., Fielding, A. K., Goldstone, A. H., Ketterling, R. P., et al. (2009) · Blood · doi:10.1182/blood-2009-08-231217 · Cited by 420
Park, J. H., Geyer, M. B., & Brentjens, R. J. (2016) · Blood · doi:10.1182/blood-2016-02-629063 · Cited by 402
Uy, G. L., Rettig, M. P., Motabi, I. H., McFarland, K., Trinkaus, K. M., Hladnik, L. M., Kulkarni, S., Abboud, C. N., Cashen, A. F., Stockerl-Goldstein, K. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-383406 · Cited by 400
Self-citationGoldberg, J. M., Silverman, L. B., Levy, D. E., Dalton, V. K., Gelber, R. D., Lehmann, L., Cohen, H. J., Sallan, S. E., & Asselin, B. L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.116 · Cited by 347
A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies
Mamonkin, M., Rouce, R. H., Tashiro, H., & Brenner, M. K. (2015) · Blood · doi:10.1182/blood-2015-02-629527 · Cited by 335
The Design of Experiments: Statistical Principles for Practical Applications.
Causton, D. R., & Mead, R. (1989) · The Journal of Ecology · doi:10.2307/2260996 · Cited by 310
MacLeod, D. T., Antony, J., Martin, A. J., Moser, R. J., Hekele, A., Wetzel, K. J., Brown, A. E., Triggiano, M. A., Hux, J. A., Pham, C. D., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.005 · Cited by 276
How I treat T-cell acute lymphoblastic leukemia in adults
Litzow, M. R., & Ferrando, A. A. (2015) · Blood · doi:10.1182/blood-2014-10-551895 · Cited by 227
Humanization of murine monoclonal antibodies through variable domain resurfacing.
Roguska, M. A., Pedersen, J. T., Keddy, C. A., Henry, A. H., Searle, S. J., Lambert, J. M., Goldmacher, V. S., Blättler, W. A., Rees, A. R., & Guild, B. C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.3.969 · Cited by 201
Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases
Osborn, M. J., Webber, B. R., Knipping, F., Lonetree, C.-L., Tennis, N., DeFeo, A. P., McElroy, A. N., Starker, C. G., Lee, C., Merkel, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.197 · Cited by 201
Png, Y. T., Vinanica, N., Kamiya, T., Shimasaki, N., Coustan-Smith, E., & Campana, D. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009928 · Cited by 187
Real-time imaging of ligand-induced IKK activation in intact cells and in living mice
Gross, S., & Piwnica-Worms, D. R. (2005) · Nature Methods · doi:10.1038/nmeth779 · Cited by 153
Pediatric T‐cell acute lymphoblastic leukemia
Karrman, K., & Johansson, B. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22416 · Cited by 137
Pinz, K. G., Liu, H.-L., Golightly, M. G., Jares, A., Lan, F., Zieve, G. W., Hagag, N. G., Schuster, M., Firor, A. E., Jiang, X., et al. (2015) · Leukemia · doi:10.1038/leu.2015.311 · Cited by 120
Patel, J. L., Smith, L. M., Anderson, J. R., Abromowitch, M., Campana, D., Jacobsen, J. R., Lones, M. A., Gross, T. G., Cairo, M. S., & Perkins, S. L. (2012) · British Journal of Haematology · doi:10.1111/bjh.12042 · Cited by 117
Milush, J. M., Long, B. R., Snyder-Cappione, J. E., Cappione, A., York, V. A., Ndhlovu, L. C., Lanier, L. L., Michaëlsson, J., & Nixon, D. F. (2009) · Blood · doi:10.1182/blood-2009-04-216374 · Cited by 106
Reinhold, U., LIU, L., Sesterhenn, J., & Abken, H. (1996) · Immunology · doi:10.1046/j.1365-2567.1996.d01-744.x · Cited by 49
T-cell lymphomas, a challenging disease: types, treatments, and future
Ma, H., & Abdul‐Hay, M. (2016) · International Journal of Clinical Oncology · doi:10.1007/s10147-016-1045-2 · Cited by 48
Targeted gene disruption of murine CD7
Bonilla, F. A. (1997) · International Immunology · doi:10.1093/intimm/9.12.1875 · Cited by 41
Jedema, I., Barge, R. M. Y., Willemze, R., & Falkenburg, J. H. F. (2003) · Leukemia · doi:10.1038/sj.leu.2402844 · Cited by 33
Eissenberg, L. G., Rettig, M. P., Ritchey, J., Prior, J. L., Schwarz, S. W., Frye, J., White, B. S., Fulton, R. S., Ghobadi, A., Cooper, M. L., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.48 · Cited by 23
Self-citation
Cited by
Mechanisms of resistance to CAR T cell therapy
Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 959
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
Enabling Technologies for Personalized and Precision Medicine
Ho, D., Quake, S. R., McCabe, E. R. B., Chng, W. J., Chow, E. K., Ding, X., Gelb, B. D., Ginsburg, G. S., Hassenstab, J., Ho, C.-M., et al. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2019.12.021 · Cited by 517
Engineering the next generation of cell-based therapeutics
Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M., & Veiseh, O. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 439
Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia
Chiesa, R., Georgiadis, C., Syed, F., Zhan, H., Etuk, A., Gkazi, S. A., Preece, R., Ottaviano, G., Braybrook, T., Chu, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2300709 · Cited by 340
Metadata
- Authors
- Cooper, M. L., Choi, J., Staser, K., Ritchey, J. K., Devenport, J. M., Eckardt, K., Rettig, M. P., Wang, B., Eissenberg, L. G., Ghobadi, A., Gehrs, L. N., Prior, J. L., Achilefu, S., Miller, C. A., Fronick, C. C., O’Neal, J., Gao, F., Weinstock, D. M., Gutierrez, A., Fulton, R. S., & DiPersio, J. F.
- Venue
- Leukemia
- Published
- 2018-02-20
- Volume
- 32
- Issue
- 9
- Pages
- 1970-1983
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2791923357
- Cited by
- 392
- References
- 34
- FWCI
- 13.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.